Patients with suspected deficiency of vitamin
B12 are at an increased risk when using this medicine. These patients must be diagnosed first for vitamin B12 deficiency. When starting treatment immediately, the combined treatment may be started for anemia
and vitamin B12 deficiency. Once the cause of anemia is identified, then the patient turned to the appropriate therapy. Daily monitoring of the blood is advised.
Folic Acid Deficiency
Patients with vitamin
B12 deficiency are at an increased risk when using folate
. When folate is used in patients having abnormal production of red blood cells with vitamin B12 deficiency, the blood-related symptoms are improved. However, the symptoms related to the nervous system may become worse. It may lead to degeneration of the lateral and posterior columns of the spinal cord (subacute combined degeneration of the spinal cord). Folic acid may mask the deficiency of vitamin B12.
The patients whose profession requires the contact of mercury
or mercury compounds are at an increased risk when using this medicine. These patients should not use the larger doses of this medicine for a long time.
Exposure to Light
The color of Mebaal may turn reddish with exposure to light and moisture. Mebaal should be used immediately when the package is opened. This medicine should not be exposed to light or moisture.
Handing of Mebaal
If the packaging sheet of this drug is swallowed, the sharp corners of this sheet may puncture the food pipe, causing hole and results in serious complications such as inflammation of the chest cavity (mediastinitis
). Caution is advised over the handling of this drug.
Long Term Use
This medicine should not be used for more than one month without any purpose unless it is effective.